Wednesday January 16, 1:01 pm Eastern Time
Press Release
SOURCE: PerkinElmer Life Sciences
PerkinElmer Life Sciences Establishes New cGMP Facility for Therapeutic Radioisotopes
New Facility to Enhance PerkinElmer Life Sciences' Yttrium 90 Offering to Customers
BOSTON--(BW HealthWire)--Jan. 16, 2002--PerkinElmer Life Sciences, the leading provider of drug discovery, life science research and clinical screening technologies and services, today announced that it is nearing completion of a new high-technology cGMP (current good manufacturing practices) manufacturing facility. Located in the Greater Boston, Massachusetts area, the facility will be used by PerkinElmer Life Sciences to produce ultra-pure Yttrium 90, a key radioisotope used to label antibodies and peptides for the radiotherapeutic treatment of cancer. This investment enables PerkinElmer to extend its product portfolio and to further partner with the broad array of pharmaceutical companies, biotechnology firms, and government institutions pursuing promising cancer therapies. PerkinElmer will complete construction by the end of the year and anticipates full production by early 2002.
The emerging field of radiotherapeutics combines ultra-pure radioisotopes with specially engineered antibodies and peptides to target tumors with powerful, highly localized cancer-killing radiation doses.
The new facility, built in compliance with cGMP and FDA guidelines, will enable PerkinElmer customers to purchase ultra-pure Yttrium 90 for use in clinical trials and specifically approved product applications.
``This investment will strengthen our world-class manufacturing capability for therapeutic radioisotopes,'' said John J. Engel, President of PerkinElmer Life Sciences. ``The new facility will provide our global customer base more flexibility as they move from research to the commercialization of cancer therapies, and it further demonstrates PerkinElmer's commitment to meeting the growing needs of our customers.''
About PerkinElmer Life Sciences
PerkinElmer Life Sciences, Inc. is a global provider of drug discovery, research, and clinical screening products, services and technologies for the life science industry. Incorporating Packard BioScience®, NEN®, Wallac(TM), and Receptor Biology(TM) product brands, PerkinElmer Life Sciences offers a complete line of instrumentation, reagents and consumables, as well as assay development, sample preparation and biochip technologies for high throughput screening, and other areas involved in target validation for drug discovery.
For more information, contact: PerkinElmer Life Sciences, 549 Albany Street, Boston, MA, 02118, USA; Telephone: (800) 551-2121 (U.S. Only) or +1 (617) 482-9595; Fax: +1 (617) 482-1380. Website: www.perkinelmer.com/lifesciences.
PerkinElmer, Inc., a high technology company based in Boston, Massachusetts, operates in three businesses -- Life Sciences, Optoelectronics and Analytical Instruments. The company has operations in over 125 countries, and is a component of the S&P 500 Index. Additional information is available at www.perkinelmer.com or at 1-877-PKI-NYSE.
--------------------------------------------------------------------------------
Contact:
Jim Monahan
PerkinElmer Life Sciences
(617) 350-9618
james.monahan@perkinelmer.com
or
Helen Shik/Jayme Maniatis
Schwartz Communications, Inc.
(781) 684-0770
perkinelmerlife@schwartz-pr.co. |
